The United Laboratories International Holdings Ltd. is an investment company, which engages in manufacturing and selling medicine products. The company employs 17,400 full-time employees The company went IPO on 2007-06-15. The firm operates its business through three segments. The Intermediate Products segment is engaged in the sale of intermediate products. The Bulk Medicine segment is engaged in the sale of bulk medicine. The Finished Products segment is engaged in the sale of antibiotics finished products, non-antibiotics finished products and capsule casings. Through its subsidiaries, the Company is also engaged in the production and sale of organic fertilizer.
The United Laboratories International Holdings Limited 的關鍵財務報表是什麼?
根據最新的財務報表(Form-10K),The United Laboratories International Holdings Limited 的總資產為 $25,833,淨isProfitable}為 $2,659
ULIHF 的關鍵財務比率是什麼?
The United Laboratories International Holdings Limited 的流動比率為 2.25,淨利潤率為 19.32,每股銷售為 $7.57。
The United Laboratories International Holdings Limited 的收入按細分市場或地理位置如何劃分?
The United Laboratories International Holdings Limited 最大收入來源為 Bulk Medicine,在最近的收益報告中收入為 6,909,415,147。就地區而言,China, including Hong Kong 是 The United Laboratories International Holdings Limited 的主要市場,收入為 12,051,782,799。
The United Laboratories International Holdings Limited 是否盈利?
是的,根據最新的財務報表,The United Laboratories International Holdings Limited 的淨利潤為 $2,659
The United Laboratories International Holdings Limited 有負債嗎?
是的,The United Laboratories International Holdings Limited 的負債為 11,444
The United Laboratories International Holdings Limited 的流通股有多少?
The United Laboratories International Holdings Limited 的總流通股為 1,817.02